Cu–ATSM: A radiopharmaceutical for the PET imaging of hypoxia

Amy L. Vāvere; Jason S. Lewis

doi:10.1039/B705989B

skip RSC | ChemSpider | Feedback

Home > Journals > Dalton Transactions > Cu–ATSM: A radiopharmac...

Authors & Referees | Librarians

You do not have JavaScript enabled. Please enable JavaScript to access the full features of the site or access our non-JavaScript page.

Dalton Transactions

Issue 43, 2007

More about this Journal
Editorial Board
Submit an Article

Follow Journal | |

Journal Home | RSC Journals

Perspective

Previous Article | Next Article

Cu–ATSM: A radiopharmaceutical for the PET imaging of hypoxia

Amy L. Vāvere and Jason S. Lewis

Dalton Trans., 2007, 4893-4902

DOI: 10.1039/B705989B
Received 23 Apr 2007, Accepted 18 Jun 2007
First published on the web 25 Sep 2007
This article is part of the collection: Dalton Discussion 10: Applications of metals in medicine and healthcare

Please wait while Download options loads

Request Permissions

Abstract
Cited by
Related Content

Copper(II)-diacetyl-bis(N⁴-methylthiosemicarbazone), Cu–ATSM, labeled with a positron emitting isotope of copper (⁶⁰Cu, ⁶¹Cu, ⁶²Cu or ⁶⁴Cu) has been shown, in vitro and in vivo, to be selective for hypoxic tissue. In silico studies have explored the mechanism of its hypoxia selectivity, and clinical studies with this agent have shown non-invasive imaging data that is predictive of a cancer patients' response to conventional therapy. This Perspective discusses the evolution of Cu–ATSM, how its selectivity can be improved upon, and where this metal–ligand platform could be taken in the future.

Terms & Conditions|Privacy |Accessibility|ACAP Enabled

Dalton Transactions

Cu–ATSM: A radiopharmaceutical for the PET imaging of hypoxia

Log in (Free Access)

Log in (Subscriber Access)

Articles By